98%
921
2 minutes
20
Background & Aims: We measured all proglucagon-derived peptides (PGDPs) levels in response to administration of three mixed meal tolerance tests (MMTs), examining differences in postprandial PGDP responses in subjects with leanness and obesity or between high-fat vs. high carbohydrate meals.
Methods: We designed three physiology interventional studies, administering MMTs over a 180-min period to individuals without diabetes after an overnight fast. In Study 1, a 450 kcal MMT was administered to n = 4 normal weight and n = 9 individuals with obesity. In Study 2, a 600 kcal high-fat MMT was administered to n = 15 normal-weight and n = 15 individuals with obesity. In Study 3, n = 32 participants with obesity were assigned to receive a 600-kcal high-fat (n = 15) or an isocaloric high-carbohydrate MMT (n = 17). Fasting and postprandial levels of c-peptide and PGDPs (proglucagon, GLP-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]) were assessed.
Results: In study 1, individuals with normal weight displayed elevated glicentin postprandial secretion compared with people with obesity (p = 0.002). Following a high-fat MMT with 33% higher energy content in study 2, all postprandial PGDPs levels were elevated (p-time<0.001), irrespective of weight status. In study 3, a prolonged postprandial upregulation of PGDPs during the high-fat MMT was observed in contrast with the acute, short-term (max 60 min) PGDP responses to a high-carbohydrate MMT (p-time∗meal<0.001). Across both studies 2 and 3, the postprandial responses of glucagon and MPGF were higher in subjects with male sex whereas glicentin was higher in subjects with female sex.
Conclusions: Fat and carbohydrate content of a meal can substantially affect the postprandial levels of PGDPs. Circulating levels of PGDPs are influenced by the energy content of the meal, and additionally, the presence of leanness or obesity affects circulating levels of select PGDPs. These results, which are to be confirmed by additional studies, expand our understanding of PGDP physiology in leanness and obesity.
Clinicaltrials: GOV REGISTRATION NUMBERS: (NCT04170010, NCT04430946, NCT04575194).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clnu.2023.06.026 | DOI Listing |
Physiol Rev
July 2025
Center for Clinical Metabolic Research, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
Proglucagon-derived peptides represent a class of peptide hormones derived from the proglucagon precursor. These peptides, including glucagon, glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2) and oxyntomodulin, exert diverse effects on several aspects of human physiology, ranging from glucose, lipid and protein metabolism to appetite regulation, nutrient absorption and gastrointestinal motility. Their actions are mediated by distinct G protein-coupled receptors, influencing endocrine, neuroendocrine, and metabolic processes, and over recent decades, the proglucagon-derived peptides have emerged as central players in the management of metabolic and gastrointestinal diseases.
View Article and Find Full Text PDFJ Am Coll Surg
May 2025
Department of Digestive Surgery, Hospital of Pasteur 2, University Hospital of Nice, Université Côte d'Azur Nice, France.
Background: Acute intestinal ischemia (AII) remains a major diagnostic challenge, associated with high morbidity and mortality. Current biomarkers lack sufficient sensitivity and specificity. Proglucagon-derived peptides constitute a family of hormones involved in the regulation of intestinal mucosal physiology.
View Article and Find Full Text PDFBiochem Pharmacol
March 2025
College of Medicine, Jiaxing University, Jiaxing 314001, PR China; Taizhou Hospital, Zhejiang University, Taizhou 317000, PR China. Electronic address:
Glucagon-like peptide 2 (GLP-2) is a proglucagon-derived peptide released by intestinal endocrine cells. However, its therapeutic potential is limited by rapid inactivation via dipeptidyl peptidase-IV. The elucidation of three-dimensional structures of G-protein-coupled receptors, including GLP-2 receptor, has facilitated the rational design of novel peptide therapeutics.
View Article and Find Full Text PDFBiomolecules
November 2024
Centre for Diabetes, School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine BT52 1SA, Northern Ireland, UK.
Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are related intestinal L-cell derived secretory products. GLP-1 has been extensively studied in terms of its influence on metabolism, but less attention has been devoted to GLP-2 in this regard. The current study compares the effects of these proglucagon-derived peptides on pancreatic beta-cell function, as well as on glucose tolerance and appetite.
View Article and Find Full Text PDFAm J Physiol Endocrinol Metab
January 2025
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, United States.
Accurate measurement of glucagon concentrations in a variety of conditions is necessary for subsequent estimation of glucagon secretion. Glucagon arises in the α-cell as a product of proglucagon processing. Modern two-site immunoassays have overcome prior problems with glucagon measurement caused by cross-reactivity with other proglucagon-derived fragments.
View Article and Find Full Text PDF